Objectives: Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors ("statins") have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19einfected older adults residing in nursing homes. Design: We undertook a retrospective multicenter cohort study to analyze the association between ACEi/ ARB and/or statin use with clinical outcome of COVID-19. The outcomes were (1) serious COVID-19 defined as long-stay hospital admission or death within 14 days of disease onset, and (2) asymptomatic (ie, no disease symptoms in the whole study period while still being diagnosed by polymerase chain reaction). Setting and participants: A total of 154 COVID-19epositive subjects were identified, residing in 1 of 2 Belgian nursing homes that experienced similar COVID-19 outbreaks. Measures: Logistic regression models were applied with age, sex, functional status, diabetes, and hypertension as covariates. Results: We found a statistically significant association between statin intake and the absence of symptoms during COVID-19 (odds ratio [OR] 2.91; confidence interval [CI] 1.27e6.71), which remained statistically significant after adjusting for covariates (OR 2.65; CI 1.13e6.68). Although the effects of statin intake on serious clinical outcome were in the same beneficial direction, these were not statistically significant (OR 0.75; CI 0.24e1.87). There was also no statistically significant association between ACEi/ ARB and asymptomatic status (OR 2.72; CI 0.59e25.1) or serious clinical outcome (OR 0.48; CI 0.10e1.97).
The expression of certain bacterial genes is regulated in a cell-density dependent way, a phenomenon called quorum sensing. Both Gram-negative and Gram-positive bacteria use this type of communication, though the signal molecules (auto-inducers) used by them differ between both groups: Gram-negative bacteria use predominantly N-acyl homoserine lacton (AHL) molecules (autoinducer-1, AI-1) while Gram-positive bacteria use mainly peptides (autoinducer peptides, AIP or quorum sensing peptides). These quorum sensing molecules are not only involved in the inter-microbial communication, but can also possibly cross-talk directly or indirectly with their host. This review summarizes the currently applied analytical approaches for quorum sensing identification and quantification with additionally summarizing the experimentally found in vivo concentrations of these molecules in humans.
Rising population density and global mobility are among the reasons why pathogens such as SARS-CoV-2, the virus that causes COVID-19, spread so rapidly across the globe. The policy response to such pandemics will always have to include accurate monitoring of the spread, as this provides one of the few alternatives to total lockdown. However, COVID-19 diagnosis is currently performed almost exclusively by reverse transcription polymerase chain reaction (RT-PCR). Although this is efficient, automatable, and acceptably cheap, reliance on one type of technology comes with serious caveats, as illustrated by recurring reagent and test shortages. We therefore developed an alternative diagnostic test that detects proteolytically digested SARS-CoV-2 proteins using mass spectrometry (MS). We established the Cov-MS consortium, consisting of 15 academic laboratories and several industrial partners to increase applicability, accessibility, sensitivity, and robustness of this kind of SARS-CoV-2 detection. This, in turn, gave rise to the Cov-MS Digital Incubator that allows other laboratories to join the effort, navigate, and share their optimizations and translate the assay into their clinic. As this test relies on viral proteins instead of RNA, it provides an orthogonal and complementary approach to RT-PCR using other reagents that are relatively inexpensive and widely available, as well as orthogonally skilled personnel and different instruments. Data are available via ProteomeXchange with identifier PXD022550.
In a controlled study, the effects of shortened and conventional dry periods (28.2 ± 4.6 vs. 48.8 ± 4 d) on performance of multiparous cow were evaluated. Seventy multiparous Holstein cows were randomly assigned to either a 28- or a 49-d dry period length (DPL). Nine cows were removed from the study and 61 cows were used in the statistical analysis. Cows in the 28-d DPL group were moved to close-up pen and fed only close-up ration during the dry period, whereas those in the 49-d DPL group were given a far-off diet after dry-off until 28 d before expected calving, and then fed the same diet as the cows in the 28-d DPL group. Daily milk yield production was significantly reduced in the 28-d DPL group compared with the 49-d DPL group through 210 d in milk (DIM). Neither milk protein nor milk fat was changed in experimental groups. However, fat yield tended to be greater in the 49 d DPL compared with the 28 d DPL. Cows with 28 d DPL lost less body condition in peripartum and gained more body condition score (BCS) by 150 DIM. No differences were detected in health disorders, reproduction efficiency and birth weights of calves due to shortened dry period. Our data demonstrate that a shortened dry period under employed management practices is a good management tool in attenuating negative energy balance status without adversely affecting total milk production. Key words: Dry period, management, multiparous dairy cow, performance, body condition score
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.